Sergio Alvarado, MD
Sports Medicine · El Paso, TXNPI 1841424181
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $78,736 of the $95,876 with a category attached, or 82.1%. Amgen accounts for 97.4% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $47,555, more than ten times the $674 reported in 2019. Among sports medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 205 payments — averaging $467.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$93K
- Rattan And Associates$1K
- Radius Health, Inc.$659
- Abbott$187
- Nalu Medical, Inc.$131
- Avanos Medical$86
- plus $240 from 8 others
Across 12 payments — averaging $23,370 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$192K
- Amgen$88K
What the payments were for
- Speaking & faculty fees$78,73682%
- Travel & lodging$10,82011%
- Food & beverage$5,1115%
- Education$1,2081%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 140 | $93,374 |
| Rattan And Associates | 1 | $1,200 |
| Radius Health, Inc. | 45 | $659 |
| Abbott | 4 | $187 |
| Nalu Medical, Inc. | 1 | $131 |
| Avanos Medical | 1 | $86 |
| Johnson & Johnson | 3 | $53 |
| AstraZeneca | 3 | $52 |
| Lilly USA, LLC | 2 | $41 |
| Bioventus LLC | 1 | $24 |
| AbbVie | 1 | $22 |
| Exact Sciences | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$90,582
- Prolia$1,175
- Nalu Neurostimulation System$131
- FREESTYLE LIBRE 3$125
How this compares
$95,876 in reported general payments places this provider in the 95th percentile of 437 sports medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Evenity (2 Syringes)Romosozumab-Aqqg | 327 | $1,636,336 |
| TymlosAbaloparatide | 271 | $777,944 |
| ProliaDenosumab | 360 | $630,515 |
| ForteoTeriparatide | 20 | $92,724 |
| TrulicityDulaglutide | 52 | $84,740 |
| JardianceEmpagliflozin | 24 | $38,175 |
| JanuviaSitagliptin Phosphate | 20 | $28,403 |
| OzempicSemaglutide | 21 | $24,914 |
| FarxigaDapagliflozin Propanediol | 22 | $23,829 |
| Duloxetine Hcl | 134 | $3,336 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 158 | $2,650 |
| Atorvastatin Calcium | 195 | $2,237 |
| Gabapentin | 72 | $2,101 |
| Olmesartan Medoxomil | 28 | $1,426 |
| Lisinopril | 158 | $1,244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEvenity (2 Syringes), Prolia | $93,374 | $2,266,851687 claims |
| Radius Health, Inc.Tymlos | $659 | $777,944271 claims |
| Lilly USA, LLCForteo, Trulicity | $41 | $177,46472 claims |
| Boehringer IngelheimJardiance | $17 | $38,17524 claims |
| AstraZenecaFarxiga | $52 | $23,82922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 437 sports medicine providers in Texas.
Other sports medicine in El Paso
- Thomas DeberardinoSan Antonio$3.5M
- Robert ScheinbergDallas$2.2M
- Walter LoweHouston$1.4M
- Reed BartzSunnyvale$1.2M
- James GregoryHouston$565K
- John McDonaldAustin$499K
- James McKinleyTyler$305K
- Kelechi OkorohaDallas$297K
- Leon PaulosPearland$289K
- Marc LabbeThe Woodlands$238K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.